Expression of the microRNA‑30 family in pulmonary arterial hypertension and the role of microRNA‑30d‑5p in the regulation of pulmonary arterial smooth muscle cell toxicity and apoptosis
- Fan Hu
- Hanmin Liu
- Chuan Wang
- Hanwen Li
- Lina Qiao
Affiliations: Department of Pediatrics, West China Second University Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China, State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, P.R. China
- Published online on: December 2, 2021 https://doi.org/10.3892/etm.2021.11031
Copyright: © Hu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The biological processes of pulmonary artery vascular smooth muscle cells (PA‑SMCs) and pulmonary artery endothelial cells in pulmonary arterial hypertension (PAH) are generally abnormal, with increased levels of proliferation and reduced levels of apoptosis. Although microRNAs (miRNAs/miRs) participate in a number of biological processes in a variety of diseases, such as tumors and infections, studies on the association between miRNAs and PAH are limited. In the present study, blood samples were collected from 6 patients with patent ductus arteriosus. The experimental group included 3 patients with severe PAH, while the control group included 3 patients without PAH. Microarray technology was used to detect the presence of any associated miRNAs. Moreover, a rat PAH model was established via left lung resection followed by monocrotaline injection, involving a total of 8 rats in the PAH group and 8 untreated rat in the control group. Reverse transcription‑quantitative PCR was performed to verify the expression levels of the miR‑30 family in the animal model. miR‑30d‑5p mimics and anti‑miR‑30d‑5p were transfected into primary cultured PA‑SMCs. Levels of cytotoxicity and cell apoptosis were examined, and Notch‑3 expression levels were studied using western blotting. The results of the present study demonstrated that miR‑30d‑5p expression was downregulated in both patient blood and animal models of the PAH group compared with control groups. In primary cultured PA‑SMCs, overexpression of miR‑30d‑5p attenuated the platelet‑derived growth factor‑induced toxicity of PA‑SMCs, while knockdown of miR‑30d‑5p resulted in the increased toxicity of PA‑SMCs compared with control group. The apoptosis rate of PA‑SMCs increased with the overexpression of miR‑30d‑5p compared with control group. Moreover, the expression levels of Notch‑3 in the miR‑30d‑5p group were significantly reduced compared with the anti‑miR‑30d‑5p and miR‑NC groups. In total, 10 circulating miRNAs that may be associated with PAH were discovered in the present study. Moreover, the expression of the miR‑30 family was verified in animal models in vivo, and seven miRNAs in this family were discovered that may be associated with PAH. Additionally, miR‑30d‑5p was downregulated in both patients with PAH and animal models compared with control groups. Thus, the results of the present study demonstrated that the regulatory mechanism underlying PA‑SMCs may be via the Notch‑3 signaling pathway.